Gilead Exercises Option on MacroGenics Bispecific Program, Triggers $10M Milestone
Event summary
- Gilead exercised its option to license a preclinical bispecific program from MacroGenics under their 2022 collaboration agreement.
- The move triggers a $10 million payment to MacroGenics.
- The licensed program uses MacroGenics’ TRIDENT® platform and targets two undisclosed solid tumor indications.
- MacroGenics remains eligible for up to $1.6 billion in additional milestone payments across the collaboration.
The big picture
This deal underscores the strategic value of MacroGenics’ TRIDENT® platform in oncology, particularly for solid tumors—a challenging area for bispecific therapies. The $10 million payment is a near-term win, but the real test will be whether these programs progress to commercialization and deliver on the potential $1.6 billion in future milestones.
What we're watching
- Pipeline Progression
- Whether MacroGenics can advance additional programs under the Gilead collaboration to clinical stages.
- Revenue Realization
- The pace at which MacroGenics converts milestone payments into sustainable revenue streams.
- Industry Competition
- How this deal positions MacroGenics against peers in the bispecific antibody space.